Why are fewer Black Americans getting GLP-1s?

GLP-1s have emerged as a highly publicized miracle drug, with celebrities such as Serena Williams and Charles Barkley advocating for their use in weight loss. Initially developed to manage Type 2 diabetes - a condition characterized by elevated blood sugar levels affecting approximately 40 million Americans, predominantly impacting Black Americans - these drugs have gained recognition as a symbol of status.

A recent study analyzing data from 26 investigations across the country revealed a troubling trend: Black patients were 20 percent less likely to receive prescriptions for the latest diabetes medications like Ozempic and Wegovy compared to their white counterparts. This disparity is rooted in a long history. A century ago, diabetes was coined a "luxury disease" for affluent white and Jewish individuals, with many dismissing the notion that Black people could develop the condition.

Despite the Heckler Report of 1985, which exposed significant racial disparities in American healthcare, Black patients' diabetes was frequently attributed to lifestyle factors rather than systemic issues like inadequate housing, nutritional access, financial constraints, and healthcare inequities. The host of the video series "Kahlil Explains," Kahlil Greene, delves into the historical context surrounding race and diabetes in America to elucidate the reasons behind the ongoing inequity in access to GLP-1s and the challenges in narrowing this gap.

This issue extends beyond mere prescriptions and requires a multi-faceted approach that goes beyond medical intervention.